The short answer
Evaluation may include excisional or core biopsy, immunophenotyping, molecular studies, imaging, blood tests, and selected marrow or CNS assessment. Each result should answer a specific diagnostic, risk, or treatment question.
Evaluation may include excisional or core biopsy, immunophenotyping, molecular studies, imaging, blood tests, and selected marrow or CNS assessment.
Planning may depend on pathology subtype, stage, tumor sites, molecular findings, organ function, fitness, and prior treatment.
A result can be diagnostic, prognostic, predictive, or useful for monitoring—and these are not identical roles.
Ask which results are confirmed and which remain pending.
On this page
Choose how you want to read this
The whole article, with every detail and caution.
This page is for people reading a DLBCL pathology report. It explains the main biopsy findings, gene test results, the IPI risk score, and how these results connect to treatment.
What the biopsy shows
DLBCL is diagnosed from a lymph-node or tissue biopsy. An excisional biopsy, which removes the whole node, gave a definite diagnosis in about 98% of cases in data NCI cites. A core needle biopsy, a thinner sample, still works well and gave one in about 92%. It is reasonable to ask whether a hematopathologist, a specialist in blood and lymph tissue, reviewed your slides.
Your report will likely mention CD20, a protein on the surface of the lymphoma cells. Rituximab, a standard part of DLBCL treatment, is an antibody drug that targets CD20. The pathologist may also test whether the cancer looks more like a germinal-center cell or an activated B-cell. This is called cell-of-origin testing. Ask your team what your result means for you.
Why MYC and BCL2 findings matter
Some DLBCL cells have changes in the MYC and BCL2 genes, sometimes both. NCI says changes in the BCL2 gene or the MYC gene, or both, are linked to a particularly poor outlook. Your team may weigh this when choosing treatment. Ask whether your tissue was tested for these changes.
The International Prognostic Index
Doctors often calculate a risk score called the IPI. It adds up five factors:
- Age
- Stage
- Performance status, a measure of how well you manage daily activities
- LDH, a blood test
- How many areas outside the lymph nodes are involved
Higher scores are linked to lower five-year survival in large studies. NCI lists rates ranging from about 96% in the lowest-risk group to about 33% in the highest-risk group. The IPI is a planning tool, not a prediction for one individual.
How results connect to treatment
The standard first treatment for DLBCL is a combination called R-CHOP: rituximab plus four chemotherapy drugs. Some people may instead get Pola-R-CHP, which swaps in a drug called polatuzumab vedotin. A related but distinct fast-growing lymphoma is called primary mediastinal B-cell lymphoma. It is treated with a regimen called dose-adjusted R-EPOCH.
If DLBCL comes back, or does not respond to first treatment, options include different chemotherapy combinations. Another option is CAR T-cell therapy, a treatment that reprograms your own immune cells. NCI reports that in trials involving people with large cell lymphoma, more than 30% of participants were alive with no evidence of cancer five years after this treatment.
What's still pending
Some marker tests may still be pending when you first meet your team. Ask which results are still pending and whether they could change your plan.
What to ask your team
- Was my tissue reviewed by a hematopathologist experienced in lymphoma?
- What is my cell-of-origin result, and were MYC and BCL2 tested?
- What is my IPI score, and how does it shape the plan?
- Is R-CHOP the recommended first treatment, or does something else fit better?
- If this comes back, what would the next options be?
Sources
Common questions
Which biopsy is used to diagnose DLBCL?
A lymph-node or tissue biopsy. An excisional biopsy, which removes the whole node, gave a definite diagnosis in about 98% of cases in the data NCI cites, and a core needle biopsy, a thinner sample, in about 92%. It is reasonable to ask whether a hematopathologist, a specialist in blood and lymph tissue, reviewed the slides.
What is CD20, and why is it on my report?
It is a protein on the surface of B cells. Rituximab, a standard part of DLBCL treatment, is an antibody drug that targets CD20.
Why do MYC and BCL2 matter?
Some DLBCL cells have changes in the MYC and BCL2 genes, sometimes both. NCI says these changes are linked to a particularly poor outlook, and your team may weigh them in choosing treatment. Ask whether your tissue was tested for these changes.
What is the IPI?
The International Prognostic Index, a risk score that adds up five factors: age, stage, a fitness measure called performance status, a blood test called LDH, and how many areas outside the lymph nodes are involved. Higher scores are linked to lower five-year survival, from 96% in the lowest-risk group to 33% in the highest, per NCI. It is a planning tool, not a prediction for one individual.
What is the standard first treatment?
R-CHOP, which is rituximab plus four chemotherapy drugs. Some people may instead get Pola-R-CHP, which swaps in a drug called polatuzumab vedotin. If DLBCL comes back or does not respond to first treatment, options include different chemotherapy combinations and CAR T-cell therapy, a treatment that reprograms your own immune cells.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this guide into a short list for your care team.
Talk with a trained specialist or navigator
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-07-22 what this meansLast updated: 2026-10-02Next planned review: 2027-07-22
Review details and limits
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Words to know
Tap any term to see what it means.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.